ABVX
NASDAQAbivax SA
$86.94
-1.21 (-1.37%)
2026-10-12 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$9.95B
P/E Ratio
N/A
52W Low
52W High
$69.81
$148.83
Volume
659K
Analyst Rating
Hold
Target: $158
8 Analyst Ratings
Strong Buy
0
Buy
0
Hold
8
Sell
0
Price Target Range
Low: $149
Avg: $158
High: $166
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Employees
80
Website
abivax.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$336.1M | -$155.6M |
| 2024 | $10.8M | -1602.9% | -$176.2M | -$153.4M |
| 2023 | $4.6M | -2756.5% | -$147.7M | -$99.7M |
| 2022 | $4.6M | -1414.7% | -$60.7M | -$53.6M |
| 2021 | $37K | -111891.9% | -$42.5M | -$45.0M |
| 2026 Q1 | N/A | N/A% | -$48.5M | -$50.5M |
| 2025 Q4 | -$2.0M | 9893.9% | -$287.7M | -$71.3M |
| 2025 Q3 | N/A | N/A% | -$153.4M | -$71.3M |
| 2025 Q2 | $2.0M | -2305.2% | -$48.4M | -$33.3M |
| 2025 Q1 | N/A | N/A% | -$52.4M | -$33.2M |
| 2024 Q4 | $7.4M | -637.9% | -$52.4M | -$33.2M |
| 2024 Q3 | N/A | N/A% | -$55.2M | -$35.1M |
| 2024 Q2 | $3.4M | -1041.1% | -$38.8M | -$50.2M |